Literature DB >> 6977539

The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.

I Björk, C M Jackson, H Jörnvall, K K Lavine, K Nordling, W J Salsgiver.   

Abstract

Reactions between near equimolar amounts of antithrombin and Factors IXa or Xa resulted in the formation of a free proteolytically modified, two-chain form of the inhibitor, in addition to the inactive antithrombin-protease complexes. The modified inhibitor produced by either enzyme was electrophoretically identical with that formed in the reaction with thrombin. As in the latter reaction, the formation of the modified antithrombin by Factor Xa was increased in the presence of heparin, while only small amounts were produced by Factor IXa both in the absence and presence of the polysaccharide. NH2-terminal sequence analyses of the isolated modified inhibitor formed by Factor Xa showed that a single Arg-Ser bond in the COOH-terminal end of the inhibitor had been cleaved. This cleavage site is identical with that identified in free thrombin-modified antithrombin. The purified antithrombin-Factor IXa and antithrombin-Factor Xa complexes were dissociated by ammonia or hydroxylamine into free enzyme and a modified two-chain form of the inhibitor. Electrophoresis studies and NH2-terminal sequence analyses showed that the modified antithrombin obtained from either complex was identical with that produced in free form by the two enzymes and also with the modified inhibitor that is released from the antithrombin-thrombin complex. The fact that identical results were obtained for the reactions between antithrombin and three enzymes with different specificities strongly suggests that the observed Arg-Ser cleavage site is the active site of antithrombin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977539

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses.

Authors:  B J Darien; J Potempa; J N Moore; J Travis
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

2.  Identification of a thrombin sequence with growth factor activity on macrophages.

Authors:  R Bar-Shavit; A J Kahn; K G Mann; G D Wilner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

3.  A fragment of antithrombin that binds both heparin and thrombin.

Authors:  L Rosenfeld; I Danishefsky
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

4.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

5.  Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin.

Authors:  A Danielsson; I Björk
Journal:  Biochem J       Date:  1983-08-01       Impact factor: 3.857

Review 6.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

Review 7.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

8.  The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.

Authors:  R C Austin; W P Sheffield; R A Rachubinski; M A Blajchman
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

9.  Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.

Authors:  E G Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

10.  Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.

Authors:  T Koide; S Odani; K Takahashi; T Ono; N Sakuragawa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.